^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBC0966

    i
    Other names: IBC0966
    Associations

    News

    Trials
    Company:
    SunHo BioPharma
    Drug class:
    PD-L1 inhibitor, SIRPA antagonist
    Related drugs:
    Associations

    News

    Trials
    1year
    Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=228, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    IBC0966
    almost3years
    Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=228, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    Clinical • New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    IBC0966